The other thing that is clear is that it is clear that Lilly will be moving Donanemab quickly in to phase 3. The cognitive testing contract for that trial will be well north of US$ 10 million. Can anyone remember who is Lilly's official preferred provider for cognitive testing to their Alzheimer’s disease platform ?
CGS Price at posting:
$1.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)